This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Celldex Barzolvolimab Phase 2 Data Positive
Tech Clinical trial data

Celldex Barzolvolimab Phase 2 Data Positive

Analysis based on 8 articles · First reported Mar 01, 2026 · Last updated Mar 01, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive Phase 2 data for barzolvolimab is expected to have a positive impact on Celldex Therapeutics' stock price, as it demonstrates the drug's potential as a significant treatment option. This development could also increase investor confidence in the biotechnology sector, particularly for companies focused on immunology.

Biotechnology Pharmaceuticals
Event Summary

Celldex Therapeutics announced positive new data from the Phase 2 Open Label Extension (OLE) study of barzolvolimab for Cold Urticaria (ColdU) and Symptomatic Dermographism (SD). The data, presented at the 2026 American Academy of Allergy, Asthma & Immunology's Annual Meeting, showed that retreatment with barzolvolimab led to rapid and profound improvements in urticaria control, consistent with initial treatment responses. This suggests that barzolvolimab, a humanized monoclonal antibody targeting mast cells, can be used intermittently, reflecting real-world treatment paradigms. Celldex Therapeutics is also initiating a global Phase 3 trial for barzolvolimab in adult patients with ColdU and SD.

Key Actions
100 Celldex Therapeutics presented positive Phase 2 clinical trial data for barzolvolimab
80 Celldex Therapeutics initiated a global Phase 3 trial for barzolvolimab
Entities Involved
stock
Celldex Therapeutics
Celldex Therapeutics presented positive Phase 2 data for barzolvolimab, demonstrating its efficacy in treating Cold Urticaria and Symptomatic Dermographism. This positive data supports the drug's potential as a best-in-class treatment and strengthens Celldex Therapeutics' position in the immunology market. The company is also initiating a global Phase 3 trial for barzolvolimab.
Importance 100 Sentiment 70
per
Jonathan A. Bernstein
Jonathan A. Bernstein, a trial investigator and Professor at the University of Cincinnati College of Medicine, presented the positive Phase 2 data for barzolvolimab. His involvement lends credibility to the study findings.
Importance 40 Sentiment 20
per
Diane Young
Diane Young, Senior Vice President and Chief Medical Officer of Celldex Therapeutics, provided commentary on the significance of barzolvolimab's retreatment efficacy and its potential to offer flexible, real-world treatment options for patients.
Importance 30 Sentiment 20
ngo
American Academy of Allergy, Asthma, and Immunology
The American Academy of Allergy, Asthma, and Immunology's Annual Meeting served as the platform for Celldex Therapeutics to present its late-breaking poster data on barzolvolimab.
Importance 20 Sentiment 0
Relationships
Diane Young related ↔ Celldex Therapeutics
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.